Is Human Bocavirus Infection Associated with Gastroenteritis in Children? An Updated Systematic Review and Meta-analysis
Abstract
Background: Human bocavirus (HBoV) figures as an increased risk factor of respiratory and gastrointestinal tract infections among children. A great deal of data is available to support the pathogenic role of HBoV in acute respiratory diseases. However, the association between HBoV infection and gastroenteritis remains controversial due to the ambiguous results. The present work aims to clarify the role of HBoV as a cause of gastroenteritis in children. Methodology/Principal findings: A systematic search of the literature was carried out from 1 January 2016 to 29 August 2021 in Embase, PubMed, Scopus, Web of Science, and the Chinese bibliographic database of biomedicine (CBM). Data from included studies were analyzed by use of a random-effects model. The pooled estimates of HBoV prevalence among all cases of gastroenteritis were generated and stratified by potential confounders. The pooled odds ratio (OR) and 95% confidence interval (CI) were computed for HBoV infection in relation to the risk of gastroenteritis. The overall prevalence of HBoV in children with gastroenteritis (9.1%, 95% CI: 6.7-11.8%) was considerably higher than that detected in children without gastroenteritis (4.0%, 95% CI: 1.1-8.5%). HBoV prevalence tended to be higher in cases of gastroenteritis under five years of age (12.1%, 95% CI: 6.8-18.7%). The highest frequency of HBoV was found in Egypt (57.8%, 95% CI: 47.7-67.6%). The predominant genotypes of HBoV circulating in children with gastroenteritis…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.